CDK12 / KIN004

We are also advancing a number of other small molecule development programs, including a CDK12 inhibitor. CDK12 is an essential regulator of DNA damage response genes against which no targeted therapies are currently approved or, to our knowledge, in clinical...

FGFR2/3 / KIN-3248

Our FGFR program, KIN-3248 is a small-molecule kinase inhibitor that target cancer-associated alterations in FGFR2 and FGFR3 genes, which are among the most commonly identified oncogenic drivers detected in solid tumor cancers. KIN-3248 aims to address the primary...